couter

Koninklijke Philips NV (PHG) sells diagnostic imaging equipment, therapeutic solutions, and connected health technologies for hospitals and healthcare providers. The next catalyst is Nov 23, 2026 — FDA Remediation Progress & Regulatory Update, which will test the company’s ability to maintain compliance and advance its AI-driven imaging innovations amid ongoing regulatory scrutiny.

  • Revenue in 2025 was $17.83B, with net income of $897M, reflecting a net margin of 5.0%.
  • Revenue declined 1.0% YoY, but net income improved, suggesting margin expansion and cost control.
  • Shareholders’ equity stands at $10.99B, indicating a solid capital base.

The Read

Philips rallied 12%.2% on Q3 2026 earnings despite meeting estimates, driven by positive guidance, operational improvements, and strategic clarity that signaled stabilization and margin expansion, pushing past the bull target after a prior 0.7% rally on Q2 results.
Nov 23, 2026 — FDA Remediation Progress & Regulatory Update
Chart by TradingView

The schedule

  • Mon23Nov

    The update tests whether Philips can demonstrate progress on its regulatory remediation plan, which is critical for maintaining its market position and avoiding further scrutiny. This differs from the last update, which focused more on compliance rather than tangible progress.

  • Sun29Nov

    The showcase tests the market's reception of Philips' AI integration in medical imaging, which could influence its product mix and revenue streams. This differs from the last showcase, which had limited AI focus.

  • Fri15Jan

    The update tests how Philips' global operations are affected by potential U.S. trade policy changes, particularly regarding medical device tariffs. This differs from the last update, which focused on regulatory rather than trade policy.

  • Tue9Feb

    The earnings report tests whether Philips can meet or exceed revenue and margin expectations, which is critical for maintaining investor confidence. This differs from the last report, which had a more muted performance.

  • Tue4May

    The earnings release tests whether Philips can sustain its performance from the previous quarter, which is critical for maintaining investor confidence. This differs from the last report, which had a more mixed performance.

  • Tue27Jul

    The earnings release tests whether Philips can sustain its performance from the previous quarter, which is critical for maintaining investor confidence. This differs from the last report, which had a more mixed performance.

  • Tue26Oct

    The earnings release tests whether Philips can sustain its performance from the previous quarter, which is critical for maintaining investor confidence. This differs from the last report, which had a more mixed performance.

Past

  • Wed28Oct

    Actual outcome: Bull · $30.34 at outcome

    PHG reported EPS of 0.4, matching estimates, but the stock rallied 12.2% as positive guidance and operational improvements signaled stabilization. The focus on core margins and turnaround efforts, along with strategic clarity, drove the price above the bull target, despite the neutral earnings report.

    Q3 results focusing on core margins and operational turnaround amidst regulatory challenges.

  • Tue28Jul

    Actual outcome: Bull · $26.34 at outcome

    Philips beat earnings expectations and provided upbeat guidance, signaling stabilization in demand and improved margin expansion. The stock rallied on strong forward guidance and strategic initiatives, pushing past the bull target. The positive momentum was driven by better-than-expected results and optimism around long-term growth prospects.

    Philips reports Q2 2026 results, where investors will focus on gross margin expansion and equipment order intake against a backdrop of slowing revenue growth.